JNCE

Jounce Therapeutics Stock Price

8.23
0.34 (4.31%)
Upgrade to Real-Time
Afterhours (Closed)
8.23
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
$30.66
Canadian Level 1 + USA
Monthly Subscription
for only
$38.05
Small Cap Basic
Monthly Subscription
for only
$33.03
VAT not included
Company Name Stock Ticker Symbol Market Type
Jounce Therapeutics Inc JNCE NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.34 4.31% 8.23 20:00:00
Close Price Low Price High Price Open Price Previous Close
8.23 7.76 8.42 7.86 7.89
Bid Price Ask Price Spread News
7.80 8.54 0.74 - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
3,896 416,508 $ 8.19 $ 3,412,677 2,294,948 2.79 - 11.81
Last Trade Time Type Quantity Stock Price Currency
16:00:19 3 $ 8.23 USD

Jounce Therapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 281.59M 34.21M 17.25M $ 147.87M $ 26.97M 1.64 12.60
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% -6.55k 1.30%

more financials information »

Jounce Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical JNCE Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week10.0710.467.248.81878,597-1.84-18.27%
1 Month4.7611.814.698.303,704,8723.4772.9%
3 Months6.6011.814.438.011,360,9161.6324.7%
6 Months5.1311.814.027.48776,7253.1060.43%
1 Year3.5811.812.797.21647,1044.65129.89%
3 Years14.9229.252.668.78424,193-6.69-44.84%
5 Years18.0029.292.669.58380,943-9.77-54.28%

Jounce Therapeutics Description

Jounce Therapeutics Inc is a clinical stage immunotherapy company. The company is dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. The company's strategy is to create immunotherapies targeting a variety of the diverse cellular components of the immune system, as well as non-immune cells resident within the tumor, all of which can vary greatly among tumors within and across indications. This may provide benefit to patients with tumors across the spectrum from highly inflamed, or hot, to poorly inflamed, or cold, and especially those not well served by current therapies. Its lead product candidate, JTX-2011, is a clinical stage monoclonal antibody.


Your Recent History
NASDAQ
JNCE
Jounce The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.